Cover Image

Safety of co-vaccination with 23-valent pneumococcal polysaccharide vaccine and split influenza virus vaccine in key populations: an active surveillance study in 8 cities of Anhui province

ObjectiveTo evaluate the safety of co-vaccination with domestic 23-valent pneumococcal polysaccharide vaccine (PPSV23) and split influenza virus vaccine (sFlu) in key populations aged 3 years and older and to provide a reference for formulating co-vaccination strategies. MethodsThe study participant...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tao LI (Author), Jianwen SUN (Author), Xi LU (Author), Haiyang XU (Author), Yuhui JIN (Author), Limin GONG (Author), Yuhui CHENG (Author), Jiangshun WAN (Author), Liangliang JIANG (Author), Jing LUO (Author), Yanwei ZHAO (Author), Binbing WANG (Author)
Format:	Book
Published:	Editorial Office of Chinese Journal of Public Health, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
by: Yang Wang, et al.
Published: (2018)

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2019)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
by: Allison R. Thompson, et al.
Published: (2019)

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
by: Nobuharu Ohshima, et al.
Published: (2020)

Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups
by: Yan Liu, et al.
Published: (2021)

Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study
by: Xiang Guo, et al.
Published: (2024)

Vaccination of 23-valent pneumococcal polysaccharide vaccine and its influencing factors in the elderly aged ≥ 65 years: a cross-sectional survey in Changshu city
by: Wancheng ZHANG, et al.
Published: (2024)

Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
by: Xiaodong Sun, et al.
Published: (2021)

Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study
by: Mohammad Sadegh Rezai, et al.
Published: (2017)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
by: Lili Huang, et al.
Published: (2019)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal disease in children with acute respiratory illness: a hospital- based test-negative design study
by: Jiaming SHEN, et al.
Published: (2023)

Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial
by: Kei Nakashima, et al.
Published: (2018)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly
by: Kenji Kawakami, et al.
Published: (2018)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
by: Na Liu, et al.
Published: (2024)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older
by: Kenji Kawakami, et al.
Published: (2020)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort study
by: Moon-Sing Lee, et al.
Published: (2024)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
by: Xinren Che, et al.
Published: (2023)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude
by: Atsushi Nakamura, et al.
Published: (2020)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Pneumococcal Diseases Among the Elderly Aged 60 Years or Older: A Matched Test Negative Case-Control Study in Shanghai, China
by: Xiaodong Sun, et al.
Published: (2021)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
by: Godwin Oligbu
Published: (2020)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
by: Laura L. Hammitt, et al.
Published: (2023)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
by: R. Reyburn, et al.
Published: (2022)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)